---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000010"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-06-28T23:59:59+00:00"
generated_at: "2026-06-01T00:24:41.954332+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CHMP issues negative opinion on Translarna renewal; PTC plans re-examination

## Summary
- CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) for nmDMD.
- Negative opinion follows EC request for re-review; PTC will request re-examination per EMA guidelines.
- Marketing authorization remains in effect; Translarna expected on market through end of 2024 even if opinion upheld.
- CEO Klein: 'STRIDE real-world evidence should not be ignored'; expert panel agreed evidence shows significant efficacy.

## SEC filing metadata
- accession: 0001070081-24-000010
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-06-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000010/0001070081-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000010/tmb-20240628x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000010
- JSON: https://secwatch.observer/filing/0001070081-24-000010.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.